NCT00100750View on ClinicalTrials.gov

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

January 31, 2010

Conditions
Recurrent Breast CarcinomaStage IV Breast Cancer
Interventions
DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Tipifarnib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00100750 - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter